A new imaging technique developed by engineers at Washington University in St. Louis can give scientists a much closer look at fibril assemblies, stacks of peptides like amyloid beta, most notably ...

Beta-amyloid plaques are considered a hallmark of Alzheimer’s disease, but they’re not the sole cause of the disease and its symptoms. Alzheimer’s is a complicated disease that experts are still ...

Another piece of the dementia puzzle may finally have been found. In A Nutshell Scientists discovered ultrathin tubes (hundreds of nanometers wide) connecting brain cells that transport proteins and ...

In an unprecedented large-scale study, researchers have mapped out the first molecular events that cause harmful protein buildups in the brain of people with Alzheimer's disease. "By measuring the ...

In Alzheimer's disease, proteins like amyloid beta form clumps, known as plaques, that damage the brain. But in some people, immune cells called microglia break down these proteins before they can ...

Researchers have developed a potential new peptide-based drug delivery system by repurposing fibrils that contribute to Alzheimer’s disease pathogenesis. Researchers at the University of North ...

Ever since the controversial approval of Biogen and Eisai's Aduhelm, debate has swirled around the strength of the link between amyloid reduction and the cognitive benefits of potential Alzheimer's ...

Piller is an investigative journalist for Science. In November 2022, Dennis Selkoe, a Harvard professor of neurologic diseases and among the most celebrated and prolific Alzheimer’s researchers, ...

More than half of 95 centenarians had a low amyloid load and 9% had no amyloid, autopsy data showed. A third of centenarians had a high amyloid load comparable to Alzheimer's disease. Five ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...